• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » PhosLo gelcaps (calcium acetate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

PhosLo gelcaps (calcium acetate)

  • Profile

Profile

Contact Information

Contact: Fresenius Medical
Website: https://fmcna.com/products/pharmaceuticals/

Currently Enrolling Trials

    Show More

    General Information

    PhosLo (calcium acetate) is a phosphate binder.

    PhosLo is specifically indicated for the reduction of serum phosphorus in patients with end stage renal disease.

    PhosLo is supplied as a gelcap. Starting dose is 2 gelcaps with each meal. Titrate the dose every 2-3 weeks until acceptable serum phosphorus level is reached. Most patients require 3-4 gelcaps with each meal.

    Mechanism of Action

    PhosLo (calcium acetate) binds to the phosphate taken in through one's diet to form insoluble calcium phosphate. This is then excreted from the body without being absorbed.

    Side Effects

    Adverse events associated with the use of PhosLo capsules or gelcaps may include (but are not limited to) the following:

    • Nausea
    • Constipation
    • Vomiting
    • Stomach pains
    • Anorexia

    Clinical Trial Results

    Studies have confirmed that using calcium acetate as a phosphorus binder will control serum phosphorus levels in most dialysis outpatients.

    Approval Date: 2001-04-01
    Company Name: Fresenius Medical
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing